$ANGO

Biotech shares hit 52-week highs on Aug. 3-4, 2026, led by catalysts including upcoming quarterly reports and clinical-trial updates. AngioDynamics (ANGO) reached $15.41, citing FDA clearance for its RELIEF study and FY2026 net sales of $320.2 million. Anika (ANIK) hit $21.11 after Q2 revenue rose to $32.6 million. Pulse (PLSE) rose to $38.29 ahead of Aug. 6 results; Eloxx (ELOX) and Yarrow (YARW) also reached highs.

Nighan Warren JR (SVP Quality and Regulatory) sold 23,370 shares of ANGIODYNAMICS INC (ANGO) at $14.72 ($0.34M total) on 2026-07-30.

AngioDynamics (ANGO) held its fiscal 2026 Q4 and full-year earnings call. The company said full-year Med Tech growth was over 18% and reported Q4 revenue up 8% to $86.6 million. Q4 Med Tech revenue was $41.8 million (+16.7%). Auryon revenue was $17.8 million (+14.4%). Mechanical thrombectomy revenue was $11.1 million (-1.1%), with AlphaVac up 38.4% and AngioVac down 15.8%. Catalysts include IDE approvals for AlphaReturn and an AngioVac study.

AngioDynamics (ANGO) discussed Q4 2026 earnings call topics including Palmetto LCD adoption progress, ongoing work on consistent reimbursement, and NanoKnife interest tied to Medicare coverage. Management said BPH is larger than prostate cancer but market size is not quantified. Mechanical thrombectomy revenue declined amid competition and internal commercial changes. Q4 is expected to be highest for revenue and cash generation.

ANGIODYNAMICS INC (ANGO) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 ef20077916_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 AngioDynamics Reports Record Fiscal Year 2026 Fourth Quarter and Full Year Financial Results; Continued Execution Drives Med Tech Growth and Full-Year Profitability Delivered its seventh consecutive quarter of double-digit

Point72 Asset Management, along with Point72 Capital Advisors Inc. and Steven A. Cohen, has reported a beneficial ownership of 3,181,829 shares in AngioDynamics (ANGO), representing a 7.7% stake as of March 31, 2026. These shares are held through Point72 Associates, an investment fund managed by Point72 Asset Management, and involve shared voting and dispositive power. The filing clarifies the control relationships among the reporting entities, with Steven A. Cohen controlling both Point72 Asset Management and Point72 Capital Advisors Inc., but explicitly states that the reporting persons do not directly own these shares.

AngioDynamics (NASDAQ: ANGO) President and CEO, Jim Clemmer, will present at the Leerink Partners Global Healthcare Conference on Monday, March 9, 2026, at 1:40 p.m. ET. A live webcast of the presentation will be available on the company's website. AngioDynamics specializes in medical technology for vascular systems, cancer treatment, and patient quality of life.

AngioDynamics Inc. (ANGO) reported a fiscal second-quarter loss of $6.4 million, or 15 cents per share, adjusting to less than 1 cent per share for specific costs. The medical device maker announced revenue of $79.4 million and anticipates full-year losses between 23 to 33 cents per share, with revenue guidance of $312 million to $314 million. Its shares have grown 3% year-to-date and 46% over the past 12 months.

AngioDynamics, Inc. ( NASDAQ:ANGO ) posted stronger-than-expected first-quarter results across its Med-Tech businesses and lifted its fiscal 2026 guidance.

Shares of AngioDynamics, Inc. ( NASDAQ:ANGO ) are up Thursday after the biotechnology company raised guidance for four key financial metrics and shared positive sales performance for this past quarter.